Results 181 to 190 of about 101,852 (311)

ACTH bioassay with isolated rat adrenal cells: ACTH activity of the porcins lipotropic peptide B [PDF]

open access: yes, 1974
Baur, X.   +5 more
core   +1 more source

Early adversity and the comorbidity between metabolic disease and psychopathology

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Hierarchical diagram representing the interplay between the genetic background and early life adversities and its effect on multiple physiological processes that ultimately impact on the risk for the comorbdity between psychopathology and cardiometabolic disorders.
Ameyalli Gómez‐Ilescas   +1 more
wiley   +1 more source

68Ga-DOTATOC PET/CT in the Localization of Pituitary Tumors in Cushing's Disease. [PDF]

open access: yesEndocrinol Metab (Seoul)
Kim K   +9 more
europepmc   +1 more source

Intramuscular pathways of maladaptation in overtraining syndrome

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend The transition from adaptive overreaching to maladaptive overtraining and mechanisms through which excessive training load can lead to performance decline. Four interconnected pathophysiological domains are highlighted: neural fatigue, involving both central and peripheral components such as altered sensory feedback and reflex ...
Emily Shorter   +4 more
wiley   +1 more source

Cannabinoid exposure during pregnancy: Cardiorespiratory effects and offspring outcomes

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Prenatal exposure to cannabinoids has been investigated across human and animal studies to understand its impact on physiological development. Evidence suggests that early‐life cannabinoid exposure influence multiple developmental processes, extending beyond neurodevelopmental outcomes to potentially affect placental function ...
Luis Gustavo A. Patrone   +1 more
wiley   +1 more source

The prospective roles of exosomes in pituitary tumors. [PDF]

open access: yesFront Endocrinol (Lausanne)
Lisiewicz P   +3 more
europepmc   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

open access: yesLiver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono   +53 more
wiley   +1 more source

Home - About - Disclaimer - Privacy